These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35953263)

  • 1. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
    Aletaha D; Kerschbaumer A; Kastrati K; Dejaco C; Dougados M; McInnes IB; Sattar N; Stamm TA; Takeuchi T; Trauner M; van der Heijde D; Voshaar M; Winthrop KL; Ravelli A; Betteridge N; Burmester GR; Bijlsma JW; Bykerk V; Caporali R; Choy EH; Codreanu C; Combe B; Crow MK; de Wit M; Emery P; Fleischmann RM; Gabay C; Hetland ML; Hyrich KL; Iagnocco A; Isaacs JD; Kremer JM; Mariette X; Merkel PA; Mysler EF; Nash P; Nurmohamed MT; Pavelka K; Poor G; Rubbert-Roth A; Schulze-Koops H; Strangfeld A; Tanaka Y; Smolen JS
    Ann Rheum Dis; 2023 Jun; 82(6):773-787. PubMed ID: 35953263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
    Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D
    Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.
    Kastrati K; Aletaha D; Burmester GR; Chwala E; Dejaco C; Dougados M; McInnes IB; Ravelli A; Sattar N; Stamm TA; Takeuchi T; Trauner M; van der Heijde D; Voshaar MJH; Winthrop K; Smolen JS; Kerschbaumer A
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36260501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of IL-6 for the treatment of inflammatory diseases.
    Nishimoto N; Kishimoto T
    Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab for the treatment of adult-onset Still's disease.
    Sfriso P; Bindoli S; Doria A; Feist E; Galozzi P
    Expert Rev Clin Immunol; 2020 Feb; 16(2):129-138. PubMed ID: 31957508
    [No Abstract]   [Full Text] [Related]  

  • 6. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still's disease.
    Kaneko Y; Takeuchi T
    Expert Opin Biol Ther; 2022 Jan; 22(1):79-85. PubMed ID: 34126828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6: from bench to bedside.
    Nishimoto N; Kishimoto T
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
    Kalliolias GD; Liossis SN
    Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-IL-6 receptor antibody].
    Nishimoto N
    Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
    Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
    Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis.
    Inoue N; Shimizu M; Tsunoda S; Kawano M; Matsumura M; Yachie A
    Clin Immunol; 2016 Aug; 169():8-13. PubMed ID: 27263804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interluekin-6 inhibitors for the treatment of adult-onset Still's disease.
    Kaneko Y
    Mod Rheumatol; 2022 Jan; 32(1):12-15. PubMed ID: 34894252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the pathogenic role of IL-6 in rheumatic diseases.
    Kaneko Y; Takeuchi T
    Cytokine; 2021 Oct; 146():155645. PubMed ID: 34303949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating inflammation by blocking interleukin-1 in humans.
    Dinarello CA; van der Meer JW
    Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.
    Perdan-Pirkmajer K; Praprotnik S; Tomšič M
    Clin Rheumatol; 2010 Dec; 29(12):1465-7. PubMed ID: 20734215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
    Paul-Pletzer K
    Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
    Segú-Vergés C; Coma M; Kessel C; Smeets S; Foell D; Aldea A
    Arthritis Res Ther; 2021 Apr; 23(1):126. PubMed ID: 33892792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.